Cargando…

A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors

Introduction: Pheochromocytomas (PCCs), paragangliomas (PGLs), ganglioneuroblastomas (GNBs), and ganglioneuromas (GNs) are neuroendocrine neoplasms (NENs) that were thought to share a common embryologic origin from neural crest cells. However, they rarely occur concurrently and recurrently. We descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pozza, Carlotta, Sesti, Franz, Di Dato, Carla, Sbardella, Emilia, Pofi, Riccardo, Schiavi, Francesca, Bonifacio, Vincenzo, Isidori, Andrea M., Faggiano, Antongiulio, Lenzi, Andrea, Giannetta, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249266/
https://www.ncbi.nlm.nih.gov/pubmed/32508744
http://dx.doi.org/10.3389/fendo.2020.00234
_version_ 1783538558571642880
author Pozza, Carlotta
Sesti, Franz
Di Dato, Carla
Sbardella, Emilia
Pofi, Riccardo
Schiavi, Francesca
Bonifacio, Vincenzo
Isidori, Andrea M.
Faggiano, Antongiulio
Lenzi, Andrea
Giannetta, Elisa
author_facet Pozza, Carlotta
Sesti, Franz
Di Dato, Carla
Sbardella, Emilia
Pofi, Riccardo
Schiavi, Francesca
Bonifacio, Vincenzo
Isidori, Andrea M.
Faggiano, Antongiulio
Lenzi, Andrea
Giannetta, Elisa
author_sort Pozza, Carlotta
collection PubMed
description Introduction: Pheochromocytomas (PCCs), paragangliomas (PGLs), ganglioneuroblastomas (GNBs), and ganglioneuromas (GNs) are neuroendocrine neoplasms (NENs) that were thought to share a common embryologic origin from neural crest cells. However, they rarely occur concurrently and recurrently. We describe the case of a 40-years-old woman with “composite PCC-GN” and multiple NENs and neuroblastic tumors. Case presentation: The patient was first referred to our department at the age of 15 years for paroxysmal hypertension, headache, sweating, and watery diarrhea. Her personal history included the diagnosis of a pelvic GNB with lumbar–aortic lymph node metastases at 11 months. Her family history was positive for cerebral glioblastoma multiforme (father). An abdominal ultrasound showed a right adrenal mass that histologically was a “composite adrenal PCC-GN.” The symptoms disappeared after surgery. At the age of 20 years, the symptoms returned: computed tomography (CT) and 131I-metaiodobenzylguanidine (MIBG) scintigraphy showed an inter-aortocaval mass, found histologically to be an inter-aortocaval PGL. Her symptoms reappeared again at 28 years: CT and magnetic resonance imaging revealed four left adrenal gland nodules, found histologically to be multifocal PCCs with some atypia. Genetic screening for VHL, RET, NF1, Tp53, SDHD, SDHB, SDHC, SDHAF2, SDHAF3, SDHA, and TMEM127 was negative. Mutational analysis of the MAX gene revealed the presence of a novel heterozygous variant, c299G>C (p.Arg100Pro, NM_002382.5) that the bioinformatics prediction programs defined as noxious and causative of pathology. Conclusion: This report represents the first description of a co-occurrence of multiple composite PCC-GN and neuroblastic tumors. The long timeline of the presentation of the NENs/neuroblastic tumors from infancy to adulthood requires a lifelong follow-up for this patient. Moreover, the importance of this case lies in the presence of a novel MAX gene variant deleterious, harmful, and causative of pathology, confirmed by Sanger sequencing and never been associated before with multiple composite PCC-GN. The present case underlines the importance of precision medicine and molecular diagnoses for hereditary pheochromocytomas and paragangliomas, suggesting that when they occur in early childhood, it is necessary to perform an extensive genetic investigation and a lifelong follow-up.
format Online
Article
Text
id pubmed-7249266
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72492662020-06-05 A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors Pozza, Carlotta Sesti, Franz Di Dato, Carla Sbardella, Emilia Pofi, Riccardo Schiavi, Francesca Bonifacio, Vincenzo Isidori, Andrea M. Faggiano, Antongiulio Lenzi, Andrea Giannetta, Elisa Front Endocrinol (Lausanne) Endocrinology Introduction: Pheochromocytomas (PCCs), paragangliomas (PGLs), ganglioneuroblastomas (GNBs), and ganglioneuromas (GNs) are neuroendocrine neoplasms (NENs) that were thought to share a common embryologic origin from neural crest cells. However, they rarely occur concurrently and recurrently. We describe the case of a 40-years-old woman with “composite PCC-GN” and multiple NENs and neuroblastic tumors. Case presentation: The patient was first referred to our department at the age of 15 years for paroxysmal hypertension, headache, sweating, and watery diarrhea. Her personal history included the diagnosis of a pelvic GNB with lumbar–aortic lymph node metastases at 11 months. Her family history was positive for cerebral glioblastoma multiforme (father). An abdominal ultrasound showed a right adrenal mass that histologically was a “composite adrenal PCC-GN.” The symptoms disappeared after surgery. At the age of 20 years, the symptoms returned: computed tomography (CT) and 131I-metaiodobenzylguanidine (MIBG) scintigraphy showed an inter-aortocaval mass, found histologically to be an inter-aortocaval PGL. Her symptoms reappeared again at 28 years: CT and magnetic resonance imaging revealed four left adrenal gland nodules, found histologically to be multifocal PCCs with some atypia. Genetic screening for VHL, RET, NF1, Tp53, SDHD, SDHB, SDHC, SDHAF2, SDHAF3, SDHA, and TMEM127 was negative. Mutational analysis of the MAX gene revealed the presence of a novel heterozygous variant, c299G>C (p.Arg100Pro, NM_002382.5) that the bioinformatics prediction programs defined as noxious and causative of pathology. Conclusion: This report represents the first description of a co-occurrence of multiple composite PCC-GN and neuroblastic tumors. The long timeline of the presentation of the NENs/neuroblastic tumors from infancy to adulthood requires a lifelong follow-up for this patient. Moreover, the importance of this case lies in the presence of a novel MAX gene variant deleterious, harmful, and causative of pathology, confirmed by Sanger sequencing and never been associated before with multiple composite PCC-GN. The present case underlines the importance of precision medicine and molecular diagnoses for hereditary pheochromocytomas and paragangliomas, suggesting that when they occur in early childhood, it is necessary to perform an extensive genetic investigation and a lifelong follow-up. Frontiers Media S.A. 2020-05-19 /pmc/articles/PMC7249266/ /pubmed/32508744 http://dx.doi.org/10.3389/fendo.2020.00234 Text en Copyright © 2020 Pozza, Sesti, Di Dato, Sbardella, Pofi, Schiavi, Bonifacio, Isidori, Faggiano, Lenzi and Giannetta. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Pozza, Carlotta
Sesti, Franz
Di Dato, Carla
Sbardella, Emilia
Pofi, Riccardo
Schiavi, Francesca
Bonifacio, Vincenzo
Isidori, Andrea M.
Faggiano, Antongiulio
Lenzi, Andrea
Giannetta, Elisa
A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors
title A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors
title_full A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors
title_fullStr A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors
title_full_unstemmed A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors
title_short A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors
title_sort novel max gene mutation variant in a patient with multiple and “composite” neuroendocrine–neuroblastic tumors
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249266/
https://www.ncbi.nlm.nih.gov/pubmed/32508744
http://dx.doi.org/10.3389/fendo.2020.00234
work_keys_str_mv AT pozzacarlotta anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT sestifranz anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT didatocarla anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT sbardellaemilia anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT pofiriccardo anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT schiavifrancesca anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT bonifaciovincenzo anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT isidoriandream anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT faggianoantongiulio anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT lenziandrea anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT giannettaelisa anovelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT pozzacarlotta novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT sestifranz novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT didatocarla novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT sbardellaemilia novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT pofiriccardo novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT schiavifrancesca novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT bonifaciovincenzo novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT isidoriandream novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT faggianoantongiulio novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT lenziandrea novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors
AT giannettaelisa novelmaxgenemutationvariantinapatientwithmultipleandcompositeneuroendocrineneuroblastictumors